Abiraterone is a potent steroidal inhibitor against cytochrome P450 17alpha-hydroxylase-17,20-lyase (CYP17) with an IC50 at 4 nM. It was approved by the FDA in April 2011 to treat castration-resistant prostate cancer. A phase I/II clinical trial evaluating abiraterone acetate in advanced breast cancer patients are also underway. In preclinical studies, abiraterone has demonstrated the ability to selectively inhibit the target enzyme, resulting in inhibition of testosterone production in both the adrenals and the testes.
Technical information:
| Chemical Formula: | C24H31NO | |
| CAS #: | 154229-19-3 | |
| Molecular Weight: | 349.51 | |
| Purity: | >98% | |
| Apperance: | White solid | |
| Chemical Name: | (3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | |
| Solubility: | Up to 50 mM in DMSO |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Attard G et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742-8. |
| 2. | Attard G et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563-71. |
Other Information:
Product Specification (pdf)MSDS (pdf)
Cellagen的FlexiWash FW400自动膜/凝胶洗涤站设计用于自动Western blot膜洗涤和孵育过程。将蛋白质转移到膜上后，将膜加载到FlexiWash上以进行自动封闭，孵育和洗涤循环。用户只需要准备所需的试剂，启动印迹程序，然后让FW400进行其余操作即可。凭借独特的液体处理设计，FW400同时支持四个清洗/孵育过程，每个过程均可独立编程，并针对特定应用实现全自动。FW400也可用于蛋白质或DNA凝胶染色和脱色，或涉及重复液体处理和孵育周期的任何其他应用。
